Art Cabenuva LA denied as not medically necessary by Humana?

Humana's specific coverage criteria for art cabenuva la are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Cabenuva (Long-Acting) for Medical Necessity

A medical-necessity denial means Humana's reviewer concluded that Cabenuva has not been shown to be clinically required for your specific situation — typically because your file did not document why an oral daily ART regimen is inadequate, or because the submission lacked enough clinical detail to justify the shift to long-acting injectable therapy. Medical-necessity denials are the most common ART denial type and among the most successfully appealed.

Humana's coverage policy will list the criteria their reviewers apply. Typically these include confirmation of HIV-1 diagnosis, virologic stability or treatment experience, absence of documented resistance to the drug's components, and evidence that an injectable regimen is medically appropriate for the patient. The FDA-approved prescribing label defines the indicated population. Your appeal must map your clinical facts to each of those criteria explicitly.

## Your Federal Appeal Rights

• Internal appeal: Under ACA §2719 (for ACA-compliant plans) and ERISA §503 (for employer-sponsored plans), you are entitled to a full-and-fair review conducted by a clinical reviewer not involved in the original denial. File in writing; your denial letter states the deadline.
• External review: After an adverse internal outcome, an independent review organization reviews the case de novo. Federal law provides approximately four months from the original denial to initiate external review. Your plan documents control the exact window.
• Expedited option: If your prescriber documents that delay would seriously jeopardize your health or your ability to undergo ongoing treatment, expedited external review (typically 72-hour turnaround) is available.

## What to Gather

1. Diagnosis and current status: Lab documentation confirming HIV-1 diagnosis, most recent viral load, and CD4 count from your medical chart. 2. Treatment history with dates and outcomes: A chronological list of every ART regimen tried, including start date, stop date, and reason for change (adverse effects, adherence challenges, resistance, virologic failure). 3. Clinical severity and complexity notes: Chart notes from your HIV specialist describing the clinical picture that makes long-acting injectable therapy the appropriate next step. 4. Adherence barrier or tolerability documentation: Any documented difficulty with daily oral dosing — including records from pharmacies, care coordinators, or social workers. 5. Prescriber medical-necessity letter: A detailed letter from your prescriber that walks through each of Humana's coverage criteria and matches them to your chart, citing FDA label language where appropriate. 6. Resistance testing results (if applicable): Genotype or phenotype testing confirming susceptibility to cabotegravir and rilpivirine.

## Criteria-Mapping Structure

Print Humana's published coverage policy. List every requirement in a left column. In the right column, write the exact chart fact, lab value, or clinical note date that satisfies it. Attach this as a cover exhibit to your appeal letter. Reviewers — including independent reviewers on external appeal — decide faster and more favorably when all criteria are addressed in parallel, rather than forcing them to search through records.